A prospective, randomized, multicentre trial for the treatment of refractory status epilepticus; experiences from evaluating the effect of the novel drug candidate, NS1209

Epilepsy Research

Volumn 106, Issue 1-2, 2013, Pages 292-295

  Sabers, Anne ^a   Wolf, Peter ^b   Møller, Arne ^c,d   Rysgaard, Karen ^e   Ben Menachem, Elinor ^f  

^a University of Copenhagen   (Denmark)

^b DANISH EPILEPSY CENTRE   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e Pharmacosmos   (Denmark)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Controlled trial; NS1209; Refractory; Status epilepticus; Treatment

Indexed keywords

2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; BENZODIAZEPINE DERIVATIVE; FOSPHENYTOIN SODIUM; PHENYTOIN; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTIC STATE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NEUROPROTECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFRACTORY STATUS EPILEPTICUS; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT;

CONTROLLED TRIAL; NS1209; REFRACTORY; STATUS EPILEPTICUS; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG RESISTANCE; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, AMPA; RESEARCH DESIGN; STATUS EPILEPTICUS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 84883309332     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.04.002     Document Type: Article

References (11)

1. Dalmau J. Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia 2009, 50(Suppl. 12):58-60.
2. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., Dessain S.K., Rosenfeld M.R., Balice-Gordon R., Lynch D.R. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008, 7:1091-1098.
3. Meierkord H., Boon P., Engelsen B., Gocke K., Shorvon S., Tinuper P., Holtkamp M. EFNS guideline on the management of status epilepticus in adults. Eur. J. Neurol. 2010, 17:348-355.
4. Novy J., Logroscino G., Rossetti A.O. Refractory status epilepticus: a prospective observational study. Epilepsia 2010, 51:251-256.
5. Pitkanen A., Mathiesen C., Ronn L.C., Moller A., Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res. 2007, 74:45-54.
6. Rogawski M.A., Donevan S.D. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv. Neurol. 1999, 79:947-963.
7. Rossetti A.O., Milligan T.A., Vulliemoz S., Michaelides C., Bertschi M., Lee J.W. A randomized trial for the treatment of refractory status epilepticus. Neurocrit. Care 2011, 14:4-10.
8. Shorvon S., Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011, 134:2802-2818.
9. Silbergleit R., Lowenstein D., Durkalski V., Conwit R. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia 2011, 52(Suppl. 8):45-47.
10. Starmark J.E., Stalhammar D., Holmgren E. The Reaction Level Scale (RLS85). Manual and guidelines. Acta Neurochir. (Wien) 1988, 91:12-20.
11. Treiman D.M., Meyers P.D., Walton N.Y., Collins J.F., Colling C., Rowan A.J., Handforth A., Faught E., Calabrese V.P., Uthman B.M., Ramsay R.E., Mamdani M.B. A comparison of four treatments for generalized convulsive status epilepticus, Veterans Affairs Status Epilepticus Cooperative Study Group. N. Engl. J. Med. 1998, 339:792-798.